FOLD
Closed
Amicus Therapeutics Inc
5.84
+0.11 (+1.92%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 5.73
Day's Range: 5.66 - 5.99
Send
sign up or login to leave a comment!
When Written:
11.09
Amicus Therapeutics Inc. is a global biotechnology company that focuses on developing therapies for rare and orphan diseases. The company was founded in 2002 and is headquartered in Cranbury, New Jersey. Amicus Therapeutics has a pipeline of potential treatments for various lysosomal storage disorders, including Fabry disease, Pompe disease, and Niemann-Pick disease. The company's lead product candidate is Galafold, an oral therapy for Fabry disease that has been approved in multiple countries. Amicus Therapeutics also has a collaboration with the University of Pennsylvania to develop gene therapies for lysosomal storage disorders. The company is committed to improving the lives of patients with rare diseases through innovative research and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








